Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Leveraging external data in the design and analysis of clinical trials in neuro-oncology.

Publication ,  Journal Article
Rahman, R; Ventz, S; McDunn, J; Louv, B; Reyes-Rivera, I; Polley, M-YC; Merchant, F; Abrey, LE; Allen, JE; Aguilar, LK; Aguilar-Cordova, E ...
Published in: Lancet Oncol
October 2021

Integration of external control data, with patient-level information, in clinical trials has the potential to accelerate the development of new treatments in neuro-oncology by contextualising single-arm studies and improving decision making (eg, early stopping decisions). Based on a series of presentations at the 2020 Clinical Trials Think Tank hosted by the Society of Neuro-Oncology, we provide an overview on the use of external control data representative of the standard of care in the design and analysis of clinical trials. High-quality patient-level records, rigorous methods, and validation analyses are necessary to effectively leverage external data. We review study designs, statistical methods, risks, and potential distortions in using external data from completed trials and real-world data, as well as data sources, data sharing models, ongoing work, and applications in glioblastoma.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Lancet Oncol

DOI

EISSN

1474-5488

Publication Date

October 2021

Volume

22

Issue

10

Start / End Page

e456 / e465

Location

England

Related Subject Headings

  • Treatment Outcome
  • Research Design
  • Oncology & Carcinogenesis
  • Neurology
  • Medical Oncology
  • Information Dissemination
  • Humans
  • Glioblastoma
  • Controlled Clinical Trials as Topic
  • Brain Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rahman, R., Ventz, S., McDunn, J., Louv, B., Reyes-Rivera, I., Polley, M.-Y., … Trippa, L. (2021). Leveraging external data in the design and analysis of clinical trials in neuro-oncology. Lancet Oncol, 22(10), e456–e465. https://doi.org/10.1016/S1470-2045(21)00488-5
Rahman, Rifaquat, Steffen Ventz, Jon McDunn, Bill Louv, Irmarie Reyes-Rivera, Mei-Yin C. Polley, Fahar Merchant, et al. “Leveraging external data in the design and analysis of clinical trials in neuro-oncology.Lancet Oncol 22, no. 10 (October 2021): e456–65. https://doi.org/10.1016/S1470-2045(21)00488-5.
Rahman R, Ventz S, McDunn J, Louv B, Reyes-Rivera I, Polley M-YC, et al. Leveraging external data in the design and analysis of clinical trials in neuro-oncology. Lancet Oncol. 2021 Oct;22(10):e456–65.
Rahman, Rifaquat, et al. “Leveraging external data in the design and analysis of clinical trials in neuro-oncology.Lancet Oncol, vol. 22, no. 10, Oct. 2021, pp. e456–65. Pubmed, doi:10.1016/S1470-2045(21)00488-5.
Rahman R, Ventz S, McDunn J, Louv B, Reyes-Rivera I, Polley M-YC, Merchant F, Abrey LE, Allen JE, Aguilar LK, Aguilar-Cordova E, Arons D, Tanner K, Bagley S, Khasraw M, Cloughesy T, Wen PY, Alexander BM, Trippa L. Leveraging external data in the design and analysis of clinical trials in neuro-oncology. Lancet Oncol. 2021 Oct;22(10):e456–e465.
Journal cover image

Published In

Lancet Oncol

DOI

EISSN

1474-5488

Publication Date

October 2021

Volume

22

Issue

10

Start / End Page

e456 / e465

Location

England

Related Subject Headings

  • Treatment Outcome
  • Research Design
  • Oncology & Carcinogenesis
  • Neurology
  • Medical Oncology
  • Information Dissemination
  • Humans
  • Glioblastoma
  • Controlled Clinical Trials as Topic
  • Brain Neoplasms